Literature DB >> 28183260

Current Challenges and Opportunities for Chemoprevention of Pancreatic Cancer.

Altaf Mohammed1, Naveena B Janakiram1, Venkateshwar Madka1, Min Li1, Adam S Asch1, Chinthalapally V Rao1.   

Abstract

BACKGROUND: The incidence of pancreatic cancer (PC) is rising in parallel with the deaths caused by this malignant disease largely due to limited improvement in current treatment strategies. In spite of aggressive PC research, for the past three decades, there has been no significant improvement in the five-year survival for this cancer. Like many other cancers, it takes several years for normal pancreatic cells to transform into pancreatic precursor lesions and to further progress into invasive carcinoma. Hence there is a scope for the development of chemo-preventive strategies to inhibit/ delay/prevent progression of this disease into an advanced stage cancer.
OBJECTIVE: Chemoprevention of pancreatic cancer.
METHOD: Review of published literature. RESULTS AND
CONCLUSION: Availability of various genetically engineered mouse (GEM) models of PC has led to accelerated progress in understanding the disease and developing intervention strategies otherwise stalled for a long time. These GEM models spontaneously develop PC in a stepwise manner and mimic the disease etiology in humans. Understanding PC development from initiation to progression to metastasis is very important for early detection and prevention of PC. In this review, we focus on the current situation, the potential challenges, the progress in existing strategies and available opportunities as well as suggest key areas for research within the increasingly important area of pancreatic cancer chemoprevention. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  Pancreatic cancer; chemoprevention; drug; early detection; genetically engineered mouse models; invasive carcinoma; targets.

Mesh:

Substances:

Year:  2018        PMID: 28183260     DOI: 10.2174/0929867324666170209104453

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  4 in total

1.  DBDx-based drug combinations show highly potent therapeutic efficacy against human pancreatic cancer xenografts in athymic mice.

Authors:  Yan-Bo Zheng; Meng-Ran Zhang; Yi Li; Xiu-Jun Liu; Yong-Su Zhen
Journal:  Cancer Biol Ther       Date:  2020-06-17       Impact factor: 4.742

2.  Targeting cholecystokinin-2 receptor for pancreatic cancer chemoprevention.

Authors:  Altaf Mohammed; Naveena B Janakiram; Chen Suen; Nicole Stratton; Stanley Lightfoot; Anil Singh; Gopal Pathuri; Rebekah Ritchie; Venkateshwar Madka; Chinthalapally V Rao
Journal:  Mol Carcinog       Date:  2019-07-16       Impact factor: 4.784

3.  Bioengineered miRNA-1291 prodrug therapy in pancreatic cancer cells and patient-derived xenograft mouse models.

Authors:  Mei-Juan Tu; Pui Yan Ho; Qian-Yu Zhang; Chao Jian; Jing-Xin Qiu; Edward J Kim; Richard J Bold; Frank J Gonzalez; Huichang Bi; Ai-Ming Yu
Journal:  Cancer Lett       Date:  2018-10-30       Impact factor: 8.679

Review 4.  Biological effects and epidemiological consequences of arsenic exposure, and reagents that can ameliorate arsenic damage in vivo.

Authors:  Chinthalapally V Rao; Sanya Pal; Altaf Mohammed; Mudassir Farooqui; Mark P Doescher; Adam S Asch; Hiroshi Y Yamada
Journal:  Oncotarget       Date:  2017-05-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.